PPAR-α agonists are still on the rise: an update on clinical and experimental findings

Introduction: Non-fasting plasma triglyceride (TG) and remnant cholesterol levels, cholesterol content of triglyceride-rich lipoproteins, have been suggested to be an additional cause of cardiovascular diseases; thus, pharmacological TG-lowering with fibrates, activators of PPAR-alpha system, has been linked to risk reduction.Areas covered: This manuscript reviews available evidence on clinical trials involving highly selective PPAR-α agonists...